Yarrow Bioscience (YARW) Amortizatization of Intangibles (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Amortizatization of Intangibles came in at -$18000.0 in Q1 2026, up 94.44% YoY from -$9257.1 in Q1 2025, and up 91.59% on a QoQ basis from -$214000.0 in Q2 2025.
Yarrow Bioscience (YARW) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 7 years of Amortizatization of Intangibles data on file, last reported at -$18000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 94.44% year-over-year to -$18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (up 44.72% YoY) and the FY2025 annual result came in at -$778000.0, up 68.15% from the prior year.
- Amortizatization of Intangibles advanced to -$18000.0 in Q1 2026, from -$214000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of -$18000.0 in Q1 2026 to a low of -$777000.0 in Q1 2024.
- A 4-year average of -$406750.0 and a median of -$415000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles plunged 113.33% — and 2026, when it soared 94.44%.
- Tracing YARW's Amortizatization of Intangibles over 4 years: stood at -$255000.0 in 2023, then sank by 113.33% to -$544000.0 in 2024, then surged by 60.66% to -$214000.0 in 2025, then jumped by 91.59% to -$18000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at -$18000.0 (Q1 2026), -$214000.0 (Q2 2025), and -$324000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,000.00 |
| Jun 30, 2026 | -3,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Jun 30, 2025 | -214,000.00 |
| Jun 30, 2025 | -214,000.00 |
| Mar 31, 2025 | -324,000.00 |
| Mar 31, 2025 | -324,000.00 |
| Dec 31, 2024 | -544,000.00 |
| Dec 31, 2024 | -544,000.00 |
| Sep 30, 2024 | -506,000.00 |
| Sep 30, 2024 | -506,000.00 |
| Jun 30, 2024 | -616,000.00 |
| Jun 30, 2024 | -616,000.00 |
| Mar 31, 2024 | -777,000.00 |
| Mar 31, 2024 | -777,000.00 |
| Dec 31, 2023 | -255,000.00 |
| Dec 31, 2023 | -255,000.00 |
| Dec 31, 2019 | 137,000.00 |
| Dec 31, 2019 | 137,000.00 |